article thumbnail

Promising schizophrenia drug faces tough competition

European Pharmaceutical Review

The Luye Pharma drug demonstrated comparable bioavailability with Johnson and Johnson’s Invega Sustenna ® at steady state in a clinical trial ( NCT04922593 ). If successful, the drug is forecasted to reach sales of $63.5 GlobalData’s report showed LY03010 is expected to launch in the US in 2024. million in 2031, representing 0.6

article thumbnail

Potential blockbuster drugs to watch in 2023

European Pharmaceutical Review

Clarivate Plc has released its Drugs to Watch 2023 report — among 70 of the drugs highlighted, including potential blockbuster drugs, the majority were revealed to be personalised medicines. The report offers predictive analysis of drugs entering the market or launching key indications in 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves first Stelara biosimilar, Wezlana

European Pharmaceutical Review

The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). US sales of Stelara totalled $6.4 Like Stelara, the most serious known side effect of Wezlana is infection. billion in 2022, according to J&J’s financial results.

article thumbnail

Regeneron receives FDA response letter for aflibercept’s BLA

Pharma Leaders

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Regeneron Pharmaceuticals for its Biologics License Application (BLA) for aflibercept 8mg to treat wet diabetic macular oedema (DME), age-related macular degeneration (wAMD) and diabetic retinopathy (DR).

article thumbnail

Senju Pharmaceutical and Novaliq close agreement for dry eye disease therapy

Pharmaceutical Technology

The therapy has shown efficacy and safety in trials for patients with a history of dry eye disease and clinical Meibomian gland dysfunction. Novaliq will receive upfront and milestone payments upon achieving regulatory and sales milestones, along with royalties on NOV03 net sales in Japan. to treat dry eye disease.

article thumbnail

Celltrion’s Yuflyma receives US FDA approval for multiple conditions

Pharmaceutical Technology

Celltrion USA has received approval from the US Food and Drug Administration (FDA) for Humira (adalimumab) biosimilar, Yuflyma (adalimumab-aaty) , for multiple indications. It will be offered to patients in prefilled syringe and autoinjector administration options.

article thumbnail

Cingulate partners with Indegene for ADHD therapy

Pharmaceutical Technology

The agreement is intended for providing commercial support for CTx-1301, after receiving the US Food and Drug Administration (FDA) approval. Recently, Cingulate commenced its first Phase III trial which has been designed for evaluating CTx-1301’s safety and efficacy.